[go: up one dir, main page]

WO1996040944A3 - Complexes solubles d'heterodimeres de lmh fusionnes et de peptides, et leur utilisation - Google Patents

Complexes solubles d'heterodimeres de lmh fusionnes et de peptides, et leur utilisation Download PDF

Info

Publication number
WO1996040944A3
WO1996040944A3 PCT/US1996/010102 US9610102W WO9640944A3 WO 1996040944 A3 WO1996040944 A3 WO 1996040944A3 US 9610102 W US9610102 W US 9610102W WO 9640944 A3 WO9640944 A3 WO 9640944A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide complexes
soluble mhc
mhc heterodimer
fused
fused soluble
Prior art date
Application number
PCT/US1996/010102
Other languages
English (en)
Other versions
WO1996040944A2 (fr
Inventor
Wayne Kindsvogel
Eva Pia Reich
Jane A Gross
Shrinkant Deshpande
Paul O Sheppard
Original Assignee
Zymogenetics Inc
Anergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Anergen Inc filed Critical Zymogenetics Inc
Priority to AU63316/96A priority Critical patent/AU6331696A/en
Priority to EP96922445A priority patent/EP0833930A2/fr
Priority to JP9502204A priority patent/JPH11507238A/ja
Publication of WO1996040944A2 publication Critical patent/WO1996040944A2/fr
Publication of WO1996040944A3 publication Critical patent/WO1996040944A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur des immunomodulateurs tels que des complexes solubles d'hétérodimères fusionnés de CMH et de peptides, et sur des procédés et peptides associés. Dans l'une des variantes préférées, ces médiateurs et procédés ont trait à l'autoimmunité.
PCT/US1996/010102 1995-06-07 1996-06-07 Complexes solubles d'heterodimeres de lmh fusionnes et de peptides, et leur utilisation WO1996040944A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU63316/96A AU6331696A (en) 1995-06-07 1996-06-07 Fused soluble mhc heterodimer:peptide complexes and their uses
EP96922445A EP0833930A2 (fr) 1995-06-07 1996-06-07 Complexes solubles d'heterodimeres de lmh fusionnes et de peptides, et leur utilisation
JP9502204A JPH11507238A (ja) 1995-06-07 1996-06-07 融合した可溶性のｍｈｃヘテロダイマー：ペプチド複合体およびその使用

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US48213395A 1995-06-07 1995-06-07
US48324195A 1995-06-07 1995-06-07
US48000295A 1995-06-07 1995-06-07
US596495P 1995-10-27 1995-10-27
US08/480,002 1995-10-27
US08/482,133 1995-10-27
US08/483,241 1995-10-27
US60/005,964 1995-10-27

Publications (2)

Publication Number Publication Date
WO1996040944A2 WO1996040944A2 (fr) 1996-12-19
WO1996040944A3 true WO1996040944A3 (fr) 1997-01-23

Family

ID=27485544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010102 WO1996040944A2 (fr) 1995-06-07 1996-06-07 Complexes solubles d'heterodimeres de lmh fusionnes et de peptides, et leur utilisation

Country Status (6)

Country Link
EP (1) EP0833930A2 (fr)
JP (1) JPH11507238A (fr)
KR (1) KR19990022641A (fr)
AU (1) AU6331696A (fr)
CA (1) CA2224205A1 (fr)
WO (1) WO1996040944A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10503379A (ja) * 1994-07-29 1998-03-31 デイド・インターナショナル・インコーポレーテッド Ｍｈｃ複合体およびその用途
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
HK1039636A1 (zh) * 1998-05-05 2002-05-03 科里克萨公司 髓磷脂碱性蛋白肽及其应用
FR2778669B1 (fr) * 1998-05-14 2002-06-14 Centre Nat Rech Scient Procede d'expression d'un complexe forme d'au moins un produit du complexe majeur d'histocompatibilite et d'un peptide chez un phage, phages et complexes ainsi obtenus et leurs applications
EP2783699A1 (fr) 2003-09-05 2014-10-01 Oregon Health & Science University Molécules MHC recombinants monomères utiles pour la manipulation de lymphocytes T spécifiques d'antigènes
AU2006316036B2 (en) 2005-11-17 2011-12-15 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. A compound comprising an autoantigenic peptide and a carrier with a MHC binding motif
US8491913B2 (en) 2009-03-07 2013-07-23 Oregon Health & Science University Compositions and methods using recombinant MHC molecules for the treatment of stroke
US9260506B2 (en) 2011-04-07 2016-02-16 Oregon Health & Science University Treatment of retinal disorders with recombinant T cell receptor ligand (RTL)
WO2015051330A1 (fr) 2013-10-03 2015-04-09 Oregon Health & Science University Polypeptides recombinés comprenant des domaines α1 du cmh de classe ii
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018150A1 (fr) * 1991-04-23 1992-10-29 Anergen, Inc. Conjugues cmh permettant de traiter l'auto-immunite
WO1994024290A1 (fr) * 1993-04-08 1994-10-27 British Bio-Technology Limited Proteines resultant de la fusion entre des sequences d'acides amines antigeniques et la beta-2-microglobuline
WO1994025054A1 (fr) * 1993-04-29 1994-11-10 Andrew Atkin Vaccin de recombinaison
WO1995023814A1 (fr) * 1994-03-04 1995-09-08 National Jewish Center For Immunology And Respiratory Medicine Produit et procede de modulation de l'activite des lymphocytes t

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018150A1 (fr) * 1991-04-23 1992-10-29 Anergen, Inc. Conjugues cmh permettant de traiter l'auto-immunite
WO1994024290A1 (fr) * 1993-04-08 1994-10-27 British Bio-Technology Limited Proteines resultant de la fusion entre des sequences d'acides amines antigeniques et la beta-2-microglobuline
WO1994025054A1 (fr) * 1993-04-29 1994-11-10 Andrew Atkin Vaccin de recombinaison
WO1995023814A1 (fr) * 1994-03-04 1995-09-08 National Jewish Center For Immunology And Respiratory Medicine Produit et procede de modulation de l'activite des lymphocytes t

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H. KOZONO ET AL.: "Production of soluble MHC class II proteins with covalently bound single peptides.", NATURE, vol. 369, no. 6476, 12 May 1994 (1994-05-12), LONDON, GB, pages 151 - 154, XP002018445 *
J. FAYEN ET AL.: "Soluble human CD8alpha binds to a recombinant fusion protein which incorporates the class I MHC alpha3 domain.", THE JOURNAL OF IMMUNOLOGY, vol. 150, no. 8 part II, 15 April 1993 (1993-04-15), BALTIMORE, MD, USA, pages 288A, XP002018446 *
S. SHARMA ET AL.: "Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 88, no. 24, 15 December 1991 (1991-12-15), WASHINGTON, DC, USA, pages 11465 - 11469, XP002018447 *

Also Published As

Publication number Publication date
CA2224205A1 (fr) 1996-12-19
EP0833930A2 (fr) 1998-04-08
WO1996040944A2 (fr) 1996-12-19
KR19990022641A (ko) 1999-03-25
AU6331696A (en) 1996-12-30
JPH11507238A (ja) 1999-06-29

Similar Documents

Publication Publication Date Title
IL117850A0 (en) Altered polypeptides with increased half-life
WO1998006749A3 (fr) Proteines de fusion de classe ii du cmh, solubles, monovalentes ou polyvalentes, et utilisations associees
AU3954997A (en) Method for following and imaging a subject's three-dimensional position and orientation, method for presenting a virtual space to a subject, and systems for implementing said methods
AU2527397A (en) Fas ligand fusion proteins and their uses
AU4397297A (en) Antibody against human parathormone related peptides
AU6255096A (en) Pegylated modified proteins
WO1996040944A3 (fr) Complexes solubles d'heterodimeres de lmh fusionnes et de peptides, et leur utilisation
AU6542598A (en) Site protected protein modification
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
WO1998005684A3 (fr) Oligomeres peptidiques de liaison cmh et procedes d'utilisation
AU3382693A (en) Case, in particular cable branching case
AU4394396A (en) Modified peptides
ZA969623B (en) Fas Ligand fusion protein.
EP0911399A3 (fr) HTHBZ47, un clone apparenté à une kringle
AU5021796A (en) Recombinant human anti-lewis b antibodies
AU5550296A (en) Conotoxin peptides
AU7796291A (en) High affinity antibodies to small peptides
WO1999011783A3 (fr) Polypeptides de boite t
AU6301698A (en) Anti-hiv peptides and proteins
AU8030098A (en) Polypeptide presentation system
EP0911391A3 (fr) Clone HWHHJ20
ZA9610510B (en) Novel peptides, the preparation and use thereof.
CA2234151A1 (fr) Peptides du complexe tlp isole du carcinome de l'appareil genital et anticorps contre lesdits peptides
AU3048689A (en) Immunogenic peptides
EP0657470A3 (fr) Anticorps monoclonaux l'albumine glucosée in vivo

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 502204

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019970709216

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2224205

Country of ref document: CA

Ref country code: CA

Ref document number: 2224205

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996922445

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996922445

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970709216

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019970709216

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996922445

Country of ref document: EP